Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study

被引：0

作者：

Blas, Leandro ^{[1
]}

Shiota, Masaki ^{[1
]}

Kato, Takuma ^{[2
]}

Matsumoto, Ryuji ^{[3
]}

Tohi, Yoichiro ^{[2
]}

Sakamoto, Shinichi ^{[4
]}

Yokomizo, Akira ^{[5
]}

Kimura, Takahiro ^{[6
]}

Furukawa, Junya ^{[7
]}

Shoji, Sunao ^{[8
]}

Kume, Haruki ^{[9
]}

Goto, Takayuki ^{[10
]}

Sekine, Yoshitaka ^{[11
]}

Sakai, Yasuyuki ^{[12
]}

Matsuoka, Yoh ^{[13
]}

Hinata, Nobuyuki ^{[14
]}

Kamoto, Toshiyuki ^{[15
]}

Terada, Naoki ^{[16
]}

Akamatsu, Shusuke ^{[17
]}

Sugimoto, Mikio ^{[2
]}

Eto, Masatoshi ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[2] Kagawa Univ, Fac Med, Dept Urol, Takamatsu, Kagawa, Japan

[3] Hokkaido Univ, Dept Urol, Grad Sch Med, Sapporo, Japan

[4] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan

[5] Harasanshin Hosp, Dept Urol, Fukuoka, Japan

[6] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[7] Tokushima Univ, Grad Sch Biomed Sci, Dept Urol, Tokushima, Japan

[8] Tokai Univ, Sch Med, Dept Urol, Isehara, Kanagawa, Japan

[9] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan

[11] Gunma Univ, Grad Sch Med, Dept Urol, Maebashi, Gunma, Japan

[12] Tsuchiura Kyodo Gen Hosp, Dept Urol, Tsuchiura, Ibaraki, Japan

[13] Saitama Canc Ctr, Dept Urol, Saitama, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, Hiroshima, Japan

[15] Miyazaki Univ, Fac Med, Dept Urol, Miyazaki, Japan

[16] Univ Fukui, Fac Med Sci, Dept Urol, Fukui, Japan

[17] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2025年

关键词：

active surveillance; PRIAS; prostate cancer; prostate-specific antigen; RADICAL PROSTATECTOMY; TERM OUTCOMES; FOLLOW-UP; MEN;

D O I：

10.1111/iju.70063

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectivesTo report outcomes of active surveillance (AS) for prostate cancer in men with intermediate-risk features of International Society of Urological Pathology (ISUP) grade group 2 and/or clinical stage T2 compared with ISUP grade group 1 and clinical stage T1 in the PRIAS-JAPAN study.MethodsPatients with prostate cancer diagnosed between January 2010 and February 2024 were included in this study. PSA test, rectal examination, and re-biopsy were performed regularly. We calculated the pathological reclassification rate, program persistence rate, and subsequent treatment.ResultsData from 1302 participants were collected. After excluding patients who did not fit inclusion criteria (n = 28) or follow-up of less than 1 year (n = 208), 1066 patients were included in this analysis. The median follow-up was 42.4 months (interquartile range 17.0-72.1). There were no statistical differences in the pathological reclassification, persistence rates, and subsequent therapy between low- and intermediate-risk features.ConclusionThis preliminary study demonstrated medium-term outcomes of AS in prostate cancer with intermediate-risk features in Japan, suggesting no significant difference in the pathological reclassification, persistence rate, and subsequent therapy between low- and intermediate-risk features.

引用

页数：5

共 50 条

[41] Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach
Michael Baboudjian
Alberto Breda
Thierry Roumeguère
Alessandro Uleri
Jean-Baptiste Roche
Alae Touzani
Vito Lacetera
Jean-Baptiste Beauval
Romain Diamand
Guiseppe Simone
Olivier Windisch
Daniel Benamran
Alexandre Fourcade
Gaelle Fiard
Camille Durand-Labrunie
Mathieu Roumiguié
Francesco Sanguedolce
Marco Oderda
Eric Barret
Gaëlle Fromont
Charles Dariane
Anne-Laure Charvet
Bastien Gondran-Tellier
Cyrille Bastide
Eric Lechevallier
Joan Palou
Alain Ruffion
Roderick C. N. Van Der Bergh
Alexandre Peltier
Guillaume Ploussard
World Journal of Urology, 2023, 41 : 1301 - 1308
[42] Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance
Zambrano, Ibardo A.
Hwang, Soohyun
Basak, Ram
Spratte, Brooke Namboodri
Filson, Christopher P.
Jacobs, Bruce L.
Tan, Hung-Jui
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (09) : 388.e1 - 388.e8
[43] A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort
Kuhlmann, Paige K.
Oyekunle, Taofik
Klaassen, Zachary
Amling, Christopher L.
Aronson, William J.
Cooperberg, Matthew R.
Kane, Christopher J.
Terris, Martha K.
Freedland, Stephen J.
CANCER MEDICINE, 2023, 12 (09): : 10931 - 10938
[44] Results of active surveillance in low and intermediate risk prostate cancer
Llorente, Carlos
Diaz Goizueta, Francisco Javier
Hernandez, Virginia
Manuel de la Morena, Jose
de la Pena, Enrique
ARCHIVOS ESPANOLES DE UROLOGIA, 2014, 67 (05): : 452 - 456
[45] An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients
da Silva, Vitor
Cagiannos, Ilias
Lavallee, Luke T.
Mallick, Ranjeeta
Witiuk, Kelsey
Cnossen, Sonya
Eastham, James A.
Fergusson, Dean A.
Morash, Chris
Breau, Rodney H.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (08): : 238 - 243
[46] Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis
Mukherjee, Subhabrata
Papadopoulos, Dimitrios
Norris, Joseph M. M.
Wani, Mudassir
Madaan, Sanjeev
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)
[47] Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance
Yang, David D.
Mahal, Brandon A.
Muralidhar, Vinayak
Vastola, Marie E.
Boldbaatar, Ninjin
Labe, Shelby A.
Nezolosky, Michelle D.
Orio, Peter F., III
King, Martin T.
Martin, Neil E.
Mouw, Kent W.
Quoc-Dien Trinh
Nguyen, Paul L.
CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : 226 - 234
[48] Cause-specific mortality of low and selective intermediate-risk prostate cancer patients with active surveillance or watchful waiting
Wu, Xiangkun
Lv, Daojun
Eftekhar, Md
Cai, Chao
Zhao, Zhijian
Gu, Di
Liu, Yongda
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (01)
[49] A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment
Bokhorst, Leonard P.
Valdagni, Riccardo
Rannikko, Antti
Kakehi, Yoshiyuki
Pickles, Tom
Bangma, Chris H.
Roobol, Monique J.
EUROPEAN UROLOGY, 2016, 70 (06) : 954 - 960
[50] Stratification of patients with intermediate-risk prostate cancer
Jung, Jin-Woo
Lee, Jung Keun
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
BJU INTERNATIONAL, 2015, 115 (06) : 907 - 912

← 1 2 3 4 5 →